No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BHVN240517P40000
- 5.60
- +4.55+433.33%
15min DelayClose May 10 16:00 ET
5.68High2.41Low
2.41Open1.05Pre Close25 Volume894 Open Interest40.00Strike Price8.88KTurnover122.13%IV-2.07%PremiumMay 17, 2024Expiry Date4.31Intrinsic Value100Multiplier5DDays to Expiry1.29Time Value100Contract SizeAmericanOptions Type-0.7469Delta0.0588Gamma7.07Leverage Ratio-0.1512Theta-0.0044Rho-5.28Eff Leverage0.0143Vega
Intraday
- 5D
- 1D
News
Express News | Biohaven Shares Are Trading Lower After the Company Reported Q1 Financial Results
Express News | Biohaven Shares Fall 8.4% After Co Reports Wider-Than-Expected Q1 Loss
Express News | Biohaven On Thursday Reported Q1 2024 Adj. EPS $(1.77) Down From $(0.98) YoY
RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
Express News | Biohaven Ltd : RBC Cuts Target Price to $59 From $61
Comments
it's number 4, $Amylyx Pharmaceuticals(AMLX.US$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
2
$Biohaven(BHVN.US$ buying at bid at 43ish over valued
Compared to the success of $Eli Lilly and Co(LLY.US$ and $NOVO NORDISK A/S(NONOF.US$, $Pfizer(PFE.US$ had a rocky start in launching its weight-loss pill. Last December, Pfizer announced that it would discontinue the development of a twice-daily iteration of its weight loss medication danuglipron, due to its unacceptable side effect profile as revealed by a Phase 2b trial. Before that, Pfizer gave up an oral dr...
+3
11
$Biohaven(BHVN.US$
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals(XENE.US$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals(XENE.US$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more
2
$Biohaven(BHVN.US$ easy short to 37
Read more